HUP0303040A2 - Készítmények és eljárások a plazma lipoprotein szintjének és a cardiovascularis betegségek kockázati tényezőinek csökkentésére - Google Patents

Készítmények és eljárások a plazma lipoprotein szintjének és a cardiovascularis betegségek kockázati tényezőinek csökkentésére

Info

Publication number
HUP0303040A2
HUP0303040A2 HU0303040A HUP0303040A HUP0303040A2 HU P0303040 A2 HUP0303040 A2 HU P0303040A2 HU 0303040 A HU0303040 A HU 0303040A HU P0303040 A HUP0303040 A HU P0303040A HU P0303040 A2 HUP0303040 A2 HU P0303040A2
Authority
HU
Hungary
Prior art keywords
methods
compositions
risk factors
cardiovascular diseases
lowering plasma
Prior art date
Application number
HU0303040A
Other languages
English (en)
Inventor
Matthias Rath
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of HUP0303040A2 publication Critical patent/HUP0303040A2/hu
Publication of HUP0303040A3 publication Critical patent/HUP0303040A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya készítmények és módszerek az Lp(a) szintekcsökkentésére emberben. A találmány készítményeket és módszereket ad acardiovasculáris betegségek kockázati tényezőinek csökkentésére. Atalálmány továbbá terápiás alternatívákat biztosít a jelenlegigyógyászati beavatkozásokhoz a koleszterin, LDL-koleszterin,trigliceridek és más metabolit rizikófaktorok csökkentésére. Ó
HU0303040A 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein and risk factors of cardiovascular diseases HUP0303040A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (2)

Publication Number Publication Date
HUP0303040A2 true HUP0303040A2 (hu) 2003-12-29
HUP0303040A3 HUP0303040A3 (en) 2005-05-30

Family

ID=22892673

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303040A HUP0303040A3 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein and risk factors of cardiovascular diseases

Country Status (24)

Country Link
US (2) US6693129B2 (hu)
EP (1) EP1324753A2 (hu)
JP (1) JP2004525080A (hu)
KR (1) KR20030070003A (hu)
CN (1) CN100421659C (hu)
AU (2) AU1145202A (hu)
BR (1) BR0114526A (hu)
CA (1) CA2424880A1 (hu)
CZ (1) CZ20031167A3 (hu)
EE (1) EE200300136A (hu)
HR (1) HRP20030348A2 (hu)
HU (1) HUP0303040A3 (hu)
IL (2) IL155238A0 (hu)
MX (1) MXPA03002964A (hu)
NO (1) NO20031510L (hu)
NZ (2) NZ545806A (hu)
PL (1) PL212479B1 (hu)
RO (1) RO120567B1 (hu)
RU (1) RU2289406C2 (hu)
SK (1) SK5252003A3 (hu)
TR (1) TR200300594T2 (hu)
UA (1) UA77660C2 (hu)
WO (1) WO2002028379A2 (hu)
ZA (1) ZA200302772B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047682A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
DE60214849T2 (de) * 2001-02-27 2007-04-26 Nutrition 21, Inc. Chromium/biotin behandlung von dyslipidämie
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
EP1534302A4 (en) * 2002-08-22 2009-01-07 Nutrition 21 Inc ARGININILICATE / INOSITOL COMPLEX AND ITS USE
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
EP1675619A4 (en) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20080207748A1 (en) * 2007-02-22 2008-08-28 Innovation Labs, Inc. Vitamin c preparation
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
US7867524B2 (en) * 2007-10-05 2011-01-11 David Rowland Energizing formulation
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
WO2015199537A1 (en) * 2014-06-24 2015-12-30 Dedraf Holding B.V. New mineral composition
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
MX2019002468A (es) 2016-09-01 2019-09-18 Jds Therapeutics Llc Composiciones de biotinato de magnesio y metodos de uso.
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
AU2019371825B2 (en) 2018-11-02 2023-07-27 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
US20210196598A1 (en) * 2018-12-26 2021-07-01 Colgate-Palmolive Company Specific Co-Aggregation Inhibition by Arginine
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
WO2024003385A1 (en) 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
ATE323479T1 (de) * 2000-06-16 2006-05-15 Matthias Dr Med Rath Zusammensetzung für die verhinderung der glattmuskelkrankheiten, die ascorbat, arginin und magnesium enthält
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
CH694549A5 (de) * 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
EE200200585A (et) * 2001-02-14 2004-04-15 Rath Matthias Biokeemiliste ühendite kompositsioon ja selle raviotstarbeline kasutamine rakulise energiavahetuse parendamiseks
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
HRP20030348A2 (en) 2005-06-30
NZ545806A (en) 2008-04-30
JP2004525080A (ja) 2004-08-19
ZA200302772B (en) 2004-10-18
US20040157895A1 (en) 2004-08-12
NO20031510L (no) 2003-06-02
CN100421659C (zh) 2008-10-01
KR20030070003A (ko) 2003-08-27
EP1324753A2 (en) 2003-07-09
US6693129B2 (en) 2004-02-17
AU1145202A (en) 2002-04-15
PL365986A1 (en) 2005-01-24
UA77660C2 (en) 2007-01-15
PL212479B1 (pl) 2012-10-31
US7244749B2 (en) 2007-07-17
HUP0303040A3 (en) 2005-05-30
NO20031510D0 (no) 2003-04-03
EE200300136A (et) 2003-08-15
RO120567B1 (ro) 2006-04-28
BR0114526A (pt) 2005-04-26
MXPA03002964A (es) 2004-12-06
US20020094996A1 (en) 2002-07-18
CN1477959A (zh) 2004-02-25
CA2424880A1 (en) 2002-04-11
WO2002028379A3 (en) 2003-02-27
RU2289406C2 (ru) 2006-12-20
NZ525390A (en) 2006-04-28
IL155238A0 (en) 2003-11-23
IL185384A (en) 2008-06-05
AU2002211452B2 (en) 2005-10-27
TR200300594T2 (tr) 2004-10-21
SK5252003A3 (en) 2004-01-08
CZ20031167A3 (cs) 2003-12-17
WO2002028379A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
HUP0303040A2 (hu) Készítmények és eljárások a plazma lipoprotein szintjének és a cardiovascularis betegségek kockázati tényezőinek csökkentésére
HUP0303083A2 (hu) CETP-gátló és atorvasztatin terápiás kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
MXPA06000326A (es) Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones.
WO2002051439A3 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
ZA200201161B (en) Methods of treating nuclear factor-kappa B mediated diseases and disorders.
MX2007005649A (es) Carboxiamidas de azaindol.
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
AP2002002427A0 (en) Ppar compounds.
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
AU2003260484A1 (en) Method for improving the ability of patients suffering from lung diseases to participate in and benefit from pulmonary rehabilitation programs
AUPS194902A0 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
TNSN05130A1 (en) Synergistic combination compresing roflumilas and (r.r) -formoterol
AU2003229005A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2004031276A3 (en) Method of inducing maturation of dendritic cells and uses therefor
WO2005000230A3 (en) Methods of treating hyperproliferative cell disorders
AU2003266165A8 (en) Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
WO2004022103A3 (en) Foxp1 and uses thereof
EP1784179A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
GB0315783D0 (en) Use
GB0306615D0 (en) New use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees